Live Updates > Live Update Details
2026-09-17 10:34:12
At its 2026 semi-annual performance briefing held on September 17, Jianyou Pharmaceutical (603707) revealed that the high-concentration version of its adalimumab project is progressing normally, but the review and approval process for biopharmaceuticals inherently involves certain uncertainties. While its aspart insulin product has received FDA approval in the United States, it is currently in the stages of inventory preparation, customer qualification approval, and order negotiation, and has not yet achieved its first sale. The commercialization of this product in the US market will require a certain period of time.
